Parkinson's disease treatment: the current and future landscape

​​Explore Parkinson's disease and access the tools you need to better understand this complex condition. 

​

​Overview

• Parkinson's disease pathway
• Professor Roger Barker
• Parkinson's disease recombinant monoclonal antibodies
• Cerebrovascular pathology in Parkinson's disease
• Markers for mixed pathology in Parkinson's disease
• Antibody panels and kits for PD research
• ​Disease-associated markers
• Other key cell and neuronal markers from Abcam
• Alpha-synuclein proteins

​​​>> In collaboration with The MJFF, we developed a range of RabMAb® products to bring you the tools you need for Parkinson’s disease research. Please see here to find out more about these products and our partnership.

​​

Parkinson's disease pathway

Explore our interactive Parkinson's disease pathway poster to find the best products for your target of interest.

Get the pathway poster

​

Professor Roger Barker, Professor of Clinical Neuroscience, University of Cambridge

Professor Barker explains where we are with research in 2019 and how our understanding of the disease has progressed, before exploring emerging trends and therapies.

Emerging trends discussed include the role of alpha-synuclein, drug repurposing, providing ‘fertilizer’ to dopamine cells such as in GDNF trials, stem cell-derived dopamine replacement, and gene therapy.

​​​​​​

​​15:55 minutes - Professor Roger Barker, Professor of Clinical Neuroscience, University of Cambridge.

​​

​Recombinant monoclonal antibodies for Parkinson's disease research

Get reproducible, batch-to-batch consistency using recombinant monoclonal antibodies for your PD research. These are some of our best selling products. 

​

Cerebrovasular pathology in Parkinson's disease

Learn how cerebrovascular lesions may contribute to changing connectivity within the brain and result in more severe PD from Professor Angelo Antonini, Professor of Neurology at the Department of Neurosciences, University of Padova.

Here Prof. Antonini explains how people with vascular lesions in the brain differ in clinical manifestations and response to traditional PD medications from those without lesions. He also talks us through imaging tracers available for studying cerebrovascular pathology.

​​

​​​​​​

Markers for mixed pathology in Parkinson's disease

We've compiled a list of markers to help you studying mixed pathology in Parkinson's disease.

Other key cell and neuronal markers from Abcam​

Check out our range of neuronal markers for supporting your research.

Alpha-synuclein proteins

Alpha-synuclein proteins are major components of Lewy bodies, intraneuronal aggregates characteristic for Parkinson's disease. Using alpha-synuclein protein aggregates and monomers will allow you to induce Lewy body pathology in both in vivo and in vitro experiments. You can explore the Lewy body pathology with our recombinant human alpha-synuclein proteins, developed in collaboration with The MJFF.

​